ReviewDrugs & aging2023
Safety and Tolerability of Antimicrobial Agents in the Older Patient.
Review in Drugs & aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Age-Related Differences in Oral Microbiota Among Obese Patients with Periodontitis: A Systematic Review.Nutrients · 2026Pooled it
- Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- Molecular determinants of antimicrobial resistance inMicrobiology spectrum · 2026Article
- Applying a gender and equity matrix for a contextualized antimicrobial stewardship intervention in Pakistan.Health policy and planning · 2026Article
- Sepsis in Frail Older Adults: Tailored Antimicrobial Stewardship and Individualized Care Approach.Antibiotics (Basel, Switzerland) · 2026Review
- Safety of Fluoroquinolones and Cotrimoxazole in Urinary Tract Infections in Older Males.Open forum infectious diseases · 2026Article
- Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California.Open forum infectious diseases · 2026Article
- Antimicrobial Consumption and Resistance Dynamics Across Healthcare Level: Global Evidence and Stewardship Implications.Pathogens (Basel, Switzerland) · 2026Review
- Association Between Clinical Frailty and Antibiotic Resistance Among Older Patients with Fever in the Emergency Department.Antibiotics (Basel, Switzerland) · 2026Article
- CSF Leukocytes in Intracranial Infections: Diagnostic, Mechanistic, and Therapeutic Insights for Neurocritical Care.Cellular and molecular neurobiology · 2026Review
- Early discontinuation of antibiotic therapy initiated in the emergency department in older patients: a retrospective study.BMC geriatrics · 2026Observational
- Real-world pharmacovigilance assessment of meropenem-associated adverse events: age stratification and time-to-onset analysis using FAERS.Frontiers in medicine · 2026Article
- Awareness, attitudes, and self-reported clinical management of antimicrobial-associated neurocognitive adverse effects among healthcare providers in Saudi Arabia.Frontiers in pharmacology · 2026Article
- Impact of kimura-takemoto atrophy classification on first-lineFrontiers in medicine · 2026Article
- Efficacy and safety of Omadacycline in community-acquired pneumonia among elderly patients: a real-world evidence study.Frontiers in cellular and infection microbiology · 2026Article
- Risk Factors, Pathogen Distribution, and Treatment Strategies for Mortality in Elderly Patients with Pulmonary Bacterial Infections.Clinical interventions in aging · 2026Article
- Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases.Frontiers in pharmacology · 2026Article
- Pneumocystis pneumonia in older non-HIV-infected patients: a French, multicentre, retrospective, cohort study.Pneumonia (Nathan Qld.) · 2025Article
- Considerations in the Diagnosis and Management of Bronchiectasis in Older Adults.Clinics in geriatric medicine · 2025Review
- Knowledge, attitudes, and practices on rational antimicrobial use and antimicrobial resistance in Namibia: an online cross-sectional survey.Journal of global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Older patients are at high risk of infections, which often present atypically and are associated with high morbidity and mortality. Antimicrobial treatment in older individuals with infectious diseases represents a clinical challenge, causing an increasing burden on worldwide healthcare systems; immunosenescence and the coexistence of multiple comorbidities determine complex polypharmacy regimens with an increase in drug-drug interactions and spread of multidrug-resistance infections. Aging-induced pharmacokinetic and pharmacodynamic changes can additionally increase the risk of inappropriate drug dosing, with underexposure that is associated with antimicrobial resistance and overexposure that may lead to adverse effects and poor adherence because of low tolerability. These issues need to be considered when starting antimicrobial prescriptions. National and international efforts have been made towards the implementation of antimicrobial stewardship (AMS) interventions to help clinicians improve the appropriateness and safety of antimicrobial prescriptions in both acute and long-term care settings. AMS programs were shown to decrease consumption of antimicrobials and to improve safety in hospitalized patients and older nursing home residents. With the abundance of antimicrobial prescriptions and the recent emergence of multidrug resistant pathogens, an in-depth review of antimicrobial prescriptions in geriatric clinical practice is needed. This review will discuss the special considerations for older individuals needing antimicrobials, including risk factors that shape risk profiles in geriatric populations as well as an evidence-based description of antimicrobial-induced adverse events in this patient population. It will highlight agents of concern for this age group and discuss interventions to mitigate the effects of inappropriate antimicrobial prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.